Biogen Inc. (BIIB)
What changed in recent filings
- Institutions — 4 new · 1 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Biogen Inc.
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 2 → 2026 Q2: 5 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Biogen Inc.
Institutions we track that reported holding this stock in their most recent 13F.
- Point72 Asset Management0.02% of portfolio · since 2025 Q1
- National Pension Service (Korea)0.06% of portfolio · held as of 2026 Q2 or earlier
- Caisse de depot (Quebec)0.16% of portfolio · held as of 2026 Q2 or earlier
- PRIMECAP Management1.94% of portfolio · held as of 2026 Q2 or earlier
- Blackstoneunder 0.01% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
Biogen. A company of multiple-sclerosis and rare-neurological-disease drugs. It gained a new growth driver with approval of the Alzheimer's drug Leqembi.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Biogen Inc. is classified under the Biotech & Health sector. See peers below.
Biogen Inc. key financials
Based on SEC filings · as of Mar 31, 2026These figures are older than one reporting cycle — the standardized line items from the next periodic report are not in the public dataset yet.
Tap a metric name to see its meaning in the glossary.
ETFs holding Biogen Inc.
Per SEC N-PORT · 2026-06-30 · by weight · factual
BIIB on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
BIIB FAQ
What is Biogen Inc. (BIIB)?
Biogen. A company of multiple-sclerosis and rare-neurological-disease drugs. It gained a new growth driver with approval of the Alzheimer's drug Leqembi.
What sector is Biogen Inc. in?
Biogen Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Biogen Inc.'s key financials?
As of Mar 31, 2026 in SEC filings: Revenue growth (YoY) 1.2%, Operating margin 24.6%, Net margin 13.8%, ROE 7.1%, Debt-to-equity 0.34x. Definitions and interpretation are available on Stocklore.
Where can I analyze Biogen Inc. (BIIB) stock?
On Stocklore you can see BIIB's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.